Inquiry Basket
Loading ......
St. Louis encephalitis virus (SLEV) is a mosquito-borne flavivirus that represents one of the most historically significant causes of viral encephalitis in North America. First identified during a 1933 outbreak in St. Louis, Missouri, SLEV is a member of the Flaviviridae family, genus Flavivirus, and is closely related to West Nile virus (WNV), Japanese encephalitis virus (JEV), and Murray Valley encephalitis virus. Although its incidence declined dramatically after the emergence of West Nile virus in the late 1990s, SLEV remains an endemic threat across the Americas, capable of causing sporadic outbreaks with significant neurological morbidity and mortality. Understanding SLEV's virology, epidemiology, and molecular pathogenesis is essential for surveillance, diagnosis, and the development of countermeasures against this re-emerging public health concern.
Figure 1. St. louis encephalitis virus (slev): genome, and pathogenesis.
SLEV is a small, enveloped virus with a single-stranded, positive-sense RNA genome of approximately 11 kilobases. The genome encodes a single polyprotein that is co- and post-translationally cleaved by viral and host proteases into three structural proteins—capsid (C), pre-membrane/membrane (prM/M), and envelope (E)—and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5). The virus belongs to the Japanese encephalitis virus serocomplex within the Flavivirus genus, sharing significant antigenic cross-reactivity with other members, which complicates serological diagnosis.
SLEV is classified into several genotypes (I–VIII) based on phylogenetic analysis, with genotype III historically associated with most North American outbreaks. The virus is maintained in an enzootic cycle involving Culex mosquitoes (primarily Culex pipiens, Culex quinquefasciatus, and Culex tarsalis) and passerine birds, which serve as amplifying hosts. Humans are incidental dead-end hosts, as viremia levels are typically insufficient to perpetuate transmission.
SLEV is endemic throughout the continental United States, Mexico, Central America, and parts of South America, with periodic outbreaks occurring during summer and early autumn when mosquito populations peak. The virus's transmission cycle is highly dependent on environmental factors, including temperature, precipitation, and bird migration patterns. Outbreaks have historically occurred at intervals of 5–15 years, with notable epidemics in the 1930s–1970s involving hundreds to thousands of cases.
In recent decades, SLEV cases have declined significantly, partly due to improved vector control and partly due to the competitive displacement by West Nile virus, which shares similar mosquito vectors and avian hosts. However, SLEV remains a persistent threat, with sporadic cases and small clusters reported annually. Risk factors for infection include age (elderly individuals are at highest risk for severe neuroinvasive disease), immunosuppression, and residential proximity to urban or peri-urban areas with abundant Culex breeding sites.
The majority of SLEV infections are asymptomatic (approximately 90–95%). In symptomatic individuals, the incubation period ranges from 5 to 15 days. Clinical presentations span a spectrum from mild febrile illness to severe neuroinvasive disease:
SLEV pathogenesis begins with inoculation of virus into the skin via an infected mosquito bite. Initial replication occurs in dendritic cells and local macrophages, followed by lymphatic spread to regional lymph nodes and viremic dissemination. Peripheral viral replication triggers a robust innate immune response, which in most individuals clears the infection before neuroinvasion occurs. In susceptible individuals, particularly the elderly, the virus crosses the blood-brain barrier (BBB) via mechanisms that remain incompletely understood but likely involve direct infection of endothelial cells, Trojan horse transport via infected leukocytes, and disruption of tight junction integrity. Once within the central nervous system (CNS), SLEV exhibits a predilection for neurons, particularly in the thalamus, brainstem, basal ganglia, and spinal cord. Viral replication induces neuronal death through both direct cytopathic effects and immune-mediated mechanisms, including microglial activation, pro-inflammatory cytokine release (IL-6, TNF-α, IL-1β), and leukocyte infiltration. The resulting neuroinflammation contributes significantly to the neurological damage and long-term sequelae.
The replication cycle and neuropathogenesis of SLEV offer multiple points for therapeutic intervention. The following molecular targets and pathological pathways represent key areas for antiviral development and disease mitigation.
| Host Neuroinflammatory Pathways | Details |
| Microglial activation | Infected neurons and microglia release pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and chemokines (CXCL10, CCL2), recruiting peripheral leukocytes and amplifying inflammation. |
| Excitotoxicity | Glutamate release from damaged neurons contributes to excitotoxic neuronal death, a process that may be targeted with NMDA receptor antagonists. |
| Autophagy and apoptosis | SLEV infection induces both autophagy (which may be pro-viral or pro-survival) and apoptotic cell death. Modulating these pathways represents a potential therapeutic strategy. |
Diagnosis of SLEV infection relies primarily on laboratory testing, as clinical features overlap with other arboviral diseases (West Nile, La Crosse, etc.). The primary diagnostic modalities include:
No specific antiviral therapy exists for SLEV. Management is supportive and includes hospitalization for severe cases, fluid and electrolyte management, seizure control, and mechanical ventilation if required. Corticosteroids have not demonstrated consistent benefit and are not routinely recommended. Research into monoclonal antibodies, small-molecule antivirals, and therapeutic hypothermia continues, but none are currently approved.
St. Louis encephalitis virus, once the leading cause of epidemic viral encephalitis in North America, remains a persistent but often overlooked public health threat. Its complex ecology, neuroinvasive potential, and shared epidemiology with West Nile virus necessitate continued surveillance and research. The molecular targets discussed—envelope protein, NS3 protease, NS5 polymerase, NS1, and host neuroinflammatory pathways—offer promising avenues for antiviral development and improved diagnostics. As climate change and urbanization reshape vector distribution, SLEV may re-emerge as a more prominent concern, underscoring the importance of sustained investment in arbovirus research and public health preparedness.
| Target | Cat. No. | Product Name | Host | Isotype | Application | |
| SLEV Env | CABT-NS1226 | Human Anti-St. Louis Encephalitis Virus Env Monoclonal Antibody, clone 6B6C-1 | Human | IgG1 | WB, IP, ELISA | Inquiry |
| SLEV NS1 | CABT-CS262 | Magic 6 4 Mouse anti-Saint Louis Encephalitis Virus NS1 monoclonal antibody, clone MN051 | Mouse | IgG2a | ELISA(cap), LFIA | Inquiry |
| SLEV NS1 | CABT-CS263 | Magic 6 4 Mouse anti-Saint Louis Encephalitis Virus NS1 monoclonal antibody, clone MN052 | Mouse | IgG1 | ELISA(cap), LFIA | Inquiry |
| SLEV | DCABY-833 | Anti-Saint louis encephalitis virus Monoclonal antibody, Clone 7c7d-2 | Mouse | IgG2a | ELISA, IF | Inquiry |
| Target | Cat. No. | Product Name | Host | |
| SLEV | DAGA-3071 | Recombinant St. Louis encephalitis virus NS1 [His] | HEK293 | Inquiry |
Loading ......
